BACKGROUND

There is no standard of care for SCNC or t-SCNC: by definition, cold tumors do not respond to the wide array of available systemic therapies over the past few years:

- Treatment of metastatic castration-resistant prostate cancer has evolved rapidly, especially with the introduction of immune checkpoint inhibitors (ICI).
- However, no standard of care has been established for patients with SCNC or t-SCNC, which is typically a “cold” or “non-immunogenic” tumor type.

FIRST-IN-CLASS ORAL INNATE IMMUNE ACTIVATOR BXCL701 COMBINED WITH PEMBROLIZUMAB, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) OF SMALL CELL NEUROENDOCRINE (SCNC) PHENOTYPE: PHASE 2A UPDATE INTERIM RESULTS

Efficacy

Proinflammatory

- BXCL701 is an orally available innate immune activator that promotes a proinflammatory response by activating an innate immune signaling pathway.
- Pembrolizumab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, leading to the stimulation of T-cell effector function.

Patient Vignette: Patient 101-962

- PATIENT VIGNETTE
- BXCL701 + pembrolizumab showed highly encouraging and durable response rates in SCNC, for which there is no standard of care.
- All responders were MSS and/or TNM low.
- Combination of BXCL701 + pembrolizumab demonstrated manageable safety profile.
- Majority of AEs were low-grade.
- No evidence of potentiation of immune-related AEs.
- Biomarker work continues and will be presented in a future scientific meeting.

CONCLUSIONS

- BXCL701 + pembrolizumab showed highly encouraging and durable response rates in SCNC, for which there is no standard of care.
- All responders were MSS and/or TNM low.
- Combination of BXCL701 + pembrolizumab demonstrated manageable safety profile.
- Majority of AEs were low-grade.
- No evidence of potentiation of immune-related AEs.
- Biomarker work continues and will be presented in a future scientific meeting.

THANK YOU

BioXcel Therapeutics, Inc. would like to thank all patients, their families, and caregivers who made this study possible. BioXcel Therapeutics, Inc. would also like to thank the participating investigators and their staff that helped support this study and their dedication to their patients despite the additional challenges as a consequence of the COVID-19 pandemic.

CONFLICT OF INTEREST DECLARATION

Primary author Vincent O’Hollaren states that he is a scientific advisor to BioXcel Therapeutics, Inc. # Head of Oncology U.S. at BioXcel Therapeutics, Inc., which sponsors his multicenter study

ClinicTrials.gov Identifier: NCT03916046
Poster presented at the 59th Annual Prostate Cancer Foundation Scientific Retreat

CONFERENCE: Carlsbad, CA, October 27-29, 2022